Company news

Nicox SA news in 2025

Nicox SA's news releases, calls and decks from 2025, newest first.

View company

Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026

December 16, 2025

Nicox Provides First Half 2025 Financial Results

October 23, 2025

Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations

October 2, 2025

GHO Capital Sells VISUfarma to Lupin

September 29, 2025

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed

September 4, 2025

Nicox Announces Shareholder Q&A Webpage Available

August 26, 2025

Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients

August 21, 2025

Nicox Extends Existing Flexible Equity Financing

August 8, 2025

Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan

August 5, 2025

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories

July 17, 2025

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial

June 30, 2025

Decks in 2025